Free Trial

Moderna (MRNA) Stock Price, News & Analysis

Moderna logo
$43.41 -2.24 (-4.91%)
(As of 12:27 PM ET)

About Moderna Stock (NASDAQ:MRNA)

Key Stats

Today's Range
$42.58
$45.49
50-Day Range
$36.85
$63.93
52-Week Range
$35.80
$170.47
Volume
3.97 million shs
Average Volume
4.95 million shs
Market Capitalization
$16.70 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$79.50
Consensus Rating
Hold

Company Overview

Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature's DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020.

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. The company is also developing vaccines and therapeutics for other infectious diseases, such as influenza, hMPV+PIV3, respiratory syncytial virus, endemic HCoV, cytomegalovirus, human immunodeficiency virus, herpes simplex virus, Epstein-Barr virus and varicella-zoster virus.

Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors. 

As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.

Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics Inc., Metagenomi Inc., the Defense Advanced Research Projects Agency, Biomedical Advanced Research and Development Authority, Institute for Life Changing Medicines and the Bill & Melinda Gates Foundation. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. 

Moderna Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
90th Percentile Overall Score

MRNA MarketRank™: 

Moderna scored higher than 90% of companies evaluated by MarketBeat, and ranked 117th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Moderna has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 5 buy ratings, 11 hold ratings, and 4 sell ratings.

  • Amount of Analyst Coverage

    Moderna has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Moderna's stock forecast and price target.
  • Earnings Growth

    Earnings for Moderna are expected to grow in the coming year, from ($9.32) to ($8.81) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Moderna is -7.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Moderna is -7.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Moderna has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    11.62% of the float of Moderna has been sold short.
  • Short Interest Ratio / Days to Cover

    Moderna has a short interest ratio ("days to cover") of 5.8.
  • Change versus previous month

    Short interest in Moderna has recently increased by 15.94%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Moderna does not currently pay a dividend.

  • Dividend Growth

    Moderna does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.62% of the float of Moderna has been sold short.
  • Short Interest Ratio / Days to Cover

    Moderna has a short interest ratio ("days to cover") of 5.8.
  • Change versus previous month

    Short interest in Moderna has recently increased by 15.94%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Moderna has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 22 news articles for Moderna this week, compared to 23 articles on an average week.
  • Search Interest

    74 people have searched for MRNA on MarketBeat in the last 30 days. This is an increase of 12% compared to the previous 30 days.
  • MarketBeat Follows

    33 people have added Moderna to their MarketBeat watchlist in the last 30 days. This is an increase of 65% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Moderna insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $134,560.00 in company stock.

  • Percentage Held by Insiders

    15.70% of the stock of Moderna is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    75.33% of the stock of Moderna is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Moderna's insider trading history.
Receive MRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.

MRNA Stock News Headlines

Did You See Trump’s Bombshell Exec. Order 001?
Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."
Stethoscope, bunch dollars , concept expensive medicine
Is Biotech’s Bull Run Over? Examining Election Impacts (MRNA)
The biotech sector's breakout attempt post-election reversed sharply, with ETFs like IBB and XBI falling and invalidating the long-term bullish setup.
See More Headlines

MRNA Stock Analysis - Frequently Asked Questions

Moderna's stock was trading at $99.45 at the beginning of 2024. Since then, MRNA shares have decreased by 56.3% and is now trading at $43.41.
View the best growth stocks for 2024 here
.

Moderna, Inc. (NASDAQ:MRNA) released its quarterly earnings results on Thursday, November, 7th. The company reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of ($1.89) by $1.92. Moderna's revenue for the quarter was up 3.8% on a year-over-year basis.

Moderna (MRNA) raised $499 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 21,700,000 shares at a price of $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

Top institutional shareholders of Moderna include Baillie Gifford & Co. (11.05%), FMR LLC (4.52%), State Street Corp (4.38%) and Geode Capital Management LLC (1.84%). Insiders that own company stock include Stephane Bancel, Noubar Afeyan, Stephen Hoge, Shannon Thyme Klinger, Juan Andres, James M Mock, Arpa Garay and David W Meline.
View institutional ownership trends
.

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

Last Earnings
11/07/2024
Today
12/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MRNA
Fax
N/A
Employees
5,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$83.33
High Stock Price Target
$179.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+82.5%
Consensus Rating
Hold
Rating Score (0-4)
2.19
Research Coverage
21 Analysts

Profitability

Net Income
$-4,714,000,000.00
Pretax Margin
-46.31%

Debt

Sales & Book Value

Annual Sales
$5.06 billion
Book Value
$36.33 per share

Miscellaneous

Free Float
326,326,000
Market Cap
$17.57 billion
Optionable
Optionable
Beta
1.58

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:MRNA) was last updated on 12/10/2024 by MarketBeat.com Staff
From Our Partners